NMI

Across TCGA pan-cancer cohorts, NMI mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NMI data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NMI mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NMI expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

CCRCC, HNSC, and LUAD are the cancer types where NMI mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.622	0.827	.009	18	view →
HNSC	OS	Median	III,IV	1.000	0.946	.037	13	view →
LUAD	DFS	Median	III,IV	0.685	0.379	.007	10	view →
GBM	OS	Median	All	0.267	0.532	.001	9	view →
PDAC	OS	Tertile	IV	0.231	0.905	.024	6	view →
UCEC	DFS	Median	III,IV	0.889	0.460	.044	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NMI–CCRCC (DFS)

Open the CCRCC breakdown →